Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.71 USD | +0.92% | -6.55% | +14.22% |
Business Summary
Number of employees: 76
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biopharmaceutical
100.0
%
| 6 | 100.0 % | 3 | 100.0 % | -55.77% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 6 | 100.0 % | 3 | 100.0 % | -55.77% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Alexander Sapir
CEO | Chief Executive Officer | 57 | 23-06-30 |
Alan Musso
DFI | Director of Finance/CFO | 62 | 23-08-06 |
Chief Tech/Sci/R&D Officer | - | 21-06-30 | |
Leslie Leinwand
CMP | Compliance Officer | - | - |
Chief Tech/Sci/R&D Officer | 61 | 22-11-30 | |
Robert Gould
BRD | Director/Board Member | 69 | - |
Iain Fraser
PRN | Corporate Officer/Principal | - | 23-02-28 |
Kristina Storey
LAW | General Counsel | - | 22-10-31 |
Paul Bruno
PRN | Corporate Officer/Principal | - | 18-12-31 |
Comptroller/Controller/Auditor | - | 22-03-10 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
James Geraghty
BRD | Director/Board Member | 69 | 16-07-18 |
Director/Board Member | 70 | 16-11-30 | |
James Collins
BRD | Director/Board Member | 58 | 16-12-31 |
Robert Gould
BRD | Director/Board Member | 69 | - |
Kathryn Haviland
CHM | Chairman | 48 | 18-06-26 |
Katina Dorton
BRD | Director/Board Member | 66 | 20-01-01 |
Alexander Sapir
CEO | Chief Executive Officer | 57 | 23-06-30 |
Sonja Banks
BRD | Director/Board Member | 55 | 21-12-07 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 62,153,638 | 61,292,675 ( 98.61 %) | 0 | 98.61 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.22% | 479M | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+45.21% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+25.72% | 12.26B | |
+27.17% | 12.05B |
- Stock Market
- Equities
- FULC Stock
- Company Fulcrum Therapeutics, Inc.